Presented by Zarko Meseldzija, CTO of American Manganese

SURREY, BC / ACCESSWIRE / August 18, 2020 / American Manganese Inc. (TSXV:AMY)(OTC PINK:AMYZF)(FSE:2AM) ("AMY" or the "Company") is pleased to announce the Advanced Lithium-ion Battery Recycling Webinar Hosted by the Critical Materials Institute and presented by Zarko Meseldzija, CTO of American Manganese Inc.

American Manganese is partnered with the U.S. Department of Energy and Critical Materials Institute in a project to advance the economic recovery of lithium-ion battery materials from electric vehicles and other consumer goods.

American Manganese has developed the patented RecycLiCo™ process that offers a closed-loop and environmentally friendly solution for the recycling of cathode materials from battery manufacturing waste (pre-consumer) and end-of-life lithium-ion batteries (post-consumer). The process achieves up to 100% recovery and high purity of materials such as lithium, cobalt, nickel, manganese, and aluminum. The RecycLiCo™ process was designed with the goal to produce recycled battery products that could be seamlessly integrated into the re-manufacturing of battery cathodes using minimal processing steps.

This is a public webinar hosted on Aug 19, 2020 12:00 PM in Mountain Time (US and Canada)

On behalf of Management

AMERICAN MANGANESE INC.
Larry W. Reaugh,
President and Chief Executive Officer
Telephone: 778 574 4444 Email: lreaugh@amymn.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release may contain "forward-looking statements", which are statements about the future based on current expectations or beliefs. For this purpose, statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements by their nature involve risks and uncertainties, and there can be no assurance that such statements will prove to be accurate or true. Investors should not place undue reliance on forward-looking statements. The Company does not undertake any obligation to update forward-looking statements except as required by law.

SOURCE: American Manganese Inc.

ReleaseID: 602319

VANCOUVER, BC / ACCESSWIRE / August 18, 2020 / LeanLife Health Inc. (CSE:LLP)(FSE:LL1) (the "Company"), a company focused on foods in the health and wellness space, is pleased to announce that it has secured exclusive US and Canadian distribution rights to IRON ENERGY, a popular line of energy drinks endorsed by boxing legend Mike Tyson.

FoodCare Group, the supplier, is one of the leaders in Poland's energy drink market and has also grown IRON ENERGY into the leading brand in the Middle East. FoodCare believes the proprietary formulations in its IRON ENERGY line will satisfy the taste profiles and energy needs of North American consumers. The annual value of the combined US and Canadian energy drink markets is estimated at over US$14 billion. Red Bull is the market leader, followed by Monster and Bang. More information on IRON ENERGY and other FoodCare products is available at: http://www.foodcare.pl/en_en/about-us.html

Under the terms of the agreement, FoodCare will supply all products for sale in the US and Canada from its production facilities in Poland. FoodCare will also provide financial and other resources to support LeanLife's marketing efforts in North America.

FoodCare Group was founded in 1984 by Wieslaw Wlodarski. The company has grown organically to become one of the leaders in the market for health-conscious consumer goods. FoodCare employs approximately 900 persons, and its products are sold in more than 50 countries.

The Company has distribution rights from FoodCare for a term of 5 years. The Company has determined requirements in Canada and the US for the importation and distribution according to prescribed regulations. The Company has received sample product for distribution in the US. A similar version with a Canadian label will be available as required. It is estimated that sales in the US will begin within 4 to 6 months, with a larger effort in 6 to 12 months. Sales in Canada are planned in 12 to 24 months.

"With Mike Tyson back in the ring, our Company as an exclusive marketing representative is ready to establish IRON ENERGY drink as one of the best-selling in North America!", said LeanLife CEO Stan Lis.

"Retailers and Distributors are expecting to capitalize on Mike Tyson's immense popularity." – Stan Lis, LeanLife CEO.

Further announcements will be launched soon about the arrival of marketing and distribution of IRON ENERGY drinks.

The Company will issue finder's fees of 10 million shares over a period of one year.

About LeanLife Health
LeanLife Health's products are long-term shelf-stable extractions from flax seed, a plentiful plant-based source of Omega-3, that give them a significant advantage as an essential fortified food ingredient. Increased Omega-3 intake, especially with LeanLife's higher Omega-3 to -6 ratio, has shown to have significant health improvement impacts.

LeanLife's mission is to provide a relatively low-cost means of replacing the less healthy vegetable oil in food, and transform them into healthier versions.

"Improving the quality of food without requiring people to change what they eat is the best way to ensure they eat healthier and benefit from an improved quality of life." – Stan Lis, CEO

LeanLife Health's industry leading and proprietary Omega-3 product formulations are of the highest quality and contain no cholesterol. Products are available in oil, emulsion and powder forms. The products can be used as food additives or as nutraceuticals and have been used to make bread, noodles, cheese, yogurt, juice and milk products for the European market.

The global Omega-3 market reached USD $33 Billion in 2016 and is expected to reach upwards of USD $57 Billion by 2025, according to a report by Grand View Research, Inc.

For more information, please contact:
Stan Lis
CEO
604-764-0518
SLis@LeanLifeHealth.com

Forward-Looking Information
Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. The Company cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond the Company's control including, the Company's ability to compete with large food companies; sales of any potential products developed will be profitable; the ability to complete sales under the sales agreement. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.

THE CSE HAS NEITHER APPROVED NOR DISAPPROVED THE INFORMATION CONTAINED HEREIN AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

SOURCE: LeanLife Health Inc.

ReleaseID: 602217

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / August 18, 2020 / CureVac N.V. ("CureVac" or the "Company"), a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), announced today the closing of its initial public offering of 15,333,332 common shares, which includes the full exercise by the underwriters of their option to purchase 1,999,999 common shares, at an initial public offering price of $16.00 per common share, for total gross proceeds of approximately $245.3 million. Concurrent with the initial public offering, Mr. Dietmar Hopp, co-founder of SAP and dievini Hopp BioTech, the company's majority shareholder, through DH-LT-Investments GmbH and affiliated entities, purchased in a private placement €100 million of common shares at the initial public offering price. The common shares began trading on The Nasdaq Global Market on August 14, 2020 under the ticker symbol "CVAC."

BofA Securities, Jefferies and Credit Suisse are acting as joint book-running managers for the offering, with Berenberg and Kempen & Co acting as passive book-running managers.

Dr. Franz-Werner Haas, Chief Executive Officer of CureVac, said: "An initial public offering is a special milestone in every company's history; and it is the culmination of months of hard work by the entire CureVac team. We continue to focus on the development and manufacturing of mRNA-based vaccines against Covid-19 and other infectious diseases, as well as product candidates in the field of oncology and protein therapy."

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission ("SEC") on August 13, 2020. The offering was made only by means of a prospectus. A copy of the final prospectus relating to the offering may be obtained for free by visiting EDGAR on the Securities and Exchange Commission's ("SEC") website at www.sec.gov. Alternatively, a copy of the final prospectus may be obtained from BofA Securities, Attention: Prospectus Department, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, by telephone at (800) 299-1322 or by email at dg.prospectus_requests@bofa.com; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at (877) 821-7388 or by email at Prospectus_Department@Jefferies.com; and Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, 6933 Louis Stephens Drive, Morrisville, North Carolina 27560, by telephone at (800) 221-1037 or by email at usa.prospectus@credit-suisse.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About CureVac

CureVac is a global clinical-stage biopharmaceutical company in the field of messenger RNA (mRNA) technology with expertise in developing and optimizing this versatile molecule for medical purposes. The principle of CureVac's proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. The company applies its technologies for the development of prophylactic vaccines, cancer therapies, antibody therapies and the treatment of rare diseases. CureVac is headquartered in Tübingen, Germany with sites in Frankfurt and Boston, USA.

CureVac Investor Relation Contact
Dr. Sarah Fakih, Vice President Investor Relations
CureVac, Tübingen, Germany
T: +49 7071 9883-1298
M: +49 160 90 496949
sarah.fakih@curevac.com

CureVac Media Contact
Thorsten Schüller, Director Corporate Communications
CureVac, Tübingen, Germany
T: +49 7071 9883-1577
thorsten.schueller@curevac.com

CureVac's Forward-Looking Statements

The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this document unless stated otherwise, and neither the delivery of this document at any time, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof.

This press release contains statements that constitute "forward looking statements" as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the Company's opinions, expectations, beliefs, plans, objectives, assumptions or projections CureVac regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of the company's strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as "anticipate," "intend," "believe," "estimate," "plan," "seek," "project," or "expect," "may," "will," "would," "could," "potential," "intend," or "should," the negative of these terms or similar expressions. Forward looking statements are based on management's current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are not a guarantee of the company's performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, including negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, ability to obtain funding, ability to conduct current and future preclinical studies and clinical trials, the timing, expense and uncertainty of regulatory approval, reliance on third parties and collaboration partners, ability to commercialize products, ability to manufacture any products, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in the company's industry, the effects of the COVID-19 pandemic on the company's business and results of operations, ability to manage growth, reliance on key personnel, reliance on intellectual property protection, ability to provide for patient safety, and fluctuations of operating results due to the effect of exchange rates or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company's control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this press release are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.

For further information, please reference the company's reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC website at www.sec.gov.

SOURCE: CureVac N.V.

ReleaseID: 602294

TORONTO, ON / ACCESSWIRE / August 18, 2020 / Artificial Intelligence company, AnalytixInsight Inc. ("AnalytixInsight", or the "Company") (TSX-V:ALY) (OTCQB:ATIXF), announces that it will be presenting at the LD 500 Virtual Conference on Tuesday, September 1st at 12 PM PST / 3 PM EST, and will host virtual one-on-one meetings with interested investors throughout the conference, which runs September 1-4. To register, or to schedule a virtual one-on-one meeting, visit ld-micro-conference.events.issuerdirect.com.

During the presentation, AnalytixInsight will also be providing an update on its FinTech subsidiary, MarketWall, who is preparing to become an online financial broker in Europe.

Presentation materials will be made available on the Company's website.

Chris Lahiji, founder of LD Micro, states, "Due to COVID, it has been nearly impossible for physical conferences to even take place. I want to show the world that you can still learn, have a great time, and see some of the most unique companies in the capital markets today. All without having to step foot outside."

ABOUT LD MICRO

Back in 2006, LD Micro began with the sole purpose of being an independent resource to the microcap world. What started as a newsletter highlighting unique companies, has transformed into the pre-eminent event platform in the space. The upcoming "500" in September is the Company's most ambitious project yet, and the first event that is accessible to everyone. For those interested in attending, please contact David Scher at david@ldmicro.com or visit www.ldmicro.com for more information.

ABOUT ANALYTIXINSIGHT INC

AnalytixInsight Inc. is an Artificial Intelligence, machine-learning company. AnalytixInsight's financial analytics platform CapitalCube.com algorithmically analyzes market price data and regulatory filings to create insightful actionable narratives and research on approximately 50,000 global companies and ETFs, providing high-quality financial research and content for investors, information providers, finance portals and media. AnalytixInsight also designs and implements Workforce Optimization solutions for large global enterprises. AnalytixInsight holds a 49% interest in MarketWall, a developer of FinTech solutions for financial institutions.

AnalytixInsight.com.

CONTACT INFORMATION:

Scott Urquhart
VP Corporate Development
Scott.Urquhart@AnalytixInsight.com

Regulatory Statements

This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. Forward-looking information includes, without limitation, statements regarding the growth of the Company's business operations; the impact to MarketWall resulting from Intesa Sanpaolo's plans, the ability for MarketWall or InvestoPro to obtain regulatory approvals to become an online broker, the impact of Covid-19 on the Company and MarketWall's business, the use of the Company's content by various parties; and the Company's future performance. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will be taken", "occur" or "be achieved". Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of AnalytixInsight Inc., as the case may be, to be materially different from those expressed or implied by such forward-looking information, including but not limited to: general business, economic, competitive, geopolitical and social uncertainties; the Company's technology and revenue generation; risks associated with operation in the technology sector; ability to successfully integrate new technology and employees; foreign operations risks; and other risks inherent in the technology industry. Although AnalytixInsight has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. AnalytixInsight does not undertake to update any forward-looking information, except in accordance with applicable securities laws.

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE

SOURCE: AnalytixInsight Inc.

ReleaseID: 602257

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

VANCOUVER, BC / ACCESSWIRE / August 18, 2020 / Softlab9 Technologies Inc. (CSE:SOFT)(OTC PINK:SOFSF)(FRA:APO2) ("SOFT" or the "Company"), is pleased to announce that its target acquisition CleanGo GreenGo ("CleanGo") has signed a supply agreement with CBIO Brand Distribution International Inc., (NASDAQ:CBIO) to supply bulk concentrate material for CBIO's SaniGenix Naturals line of hard surface disinfectants and sanitizers.

SaniGenix™ Naturals
CBIO's CPG brand SaniGenix™ Naturals offers consumers an EPA approved line of disinfectants and sanitizers for hard surfaces.

"We are so pleased to be able to offer consumers the choice to use a non-toxic green cleaner in their defence against germs. Having CleanGo GreenGo™ as our strategic supplier for SaniGenix™ Naturals adds yet another unique and high performing CPG product to CBIO's suite of brands" says Lisa Little, President and CEO.

Anthony Sarvucci, CEO of CleanGo said, "CleanGo is pleased to provide the power of emulsification to CBIO's line of products. We continue to validate our technology and the need for our product in today's sanitization market."

About CleanGo GreenGo
CleanGo GreenGo is an FDA and Health Canada approved Manufacturer of Green, Non-Toxic, and Biodegradable suite of cleaning products for industrial, commercial and consumer markets.

CleanGo GreenGo, also manufactures hand sanitizer gel which is sold throughout the USA and Canada.

CleanGo's products have been tested in 2015 in the USA to kill the human coronavirus. CleanGo's products are sold on various online platforms, including Amazon, as well as through distribution in retail, wholesale, and government agencies. CleanGo GreenGo utilizes a Patent Pending IP. The Patent was filed with the United States Patent and Trademark Office in February 2020 and currently holds a Patent Pending Status.

About SoftLab9
SoftLab9 Technologies Inc. is an international publicly traded company that specializes in the development of early staged companies. We provide access to capital, executive management and industry experience to grow our portfolio of companies.

SoftLab9's experienced team bring new ideas and innovation based on science to find solution's to the current world we live in. Customers rely on quality, nontoxic products to keep their homes clean and their loved ones safe, now more than ever during these unprecedented international public health crisis.

Cautionary Note:
The Company is not making any express or implied claims that CleanGo GreenGo or any other product has the ability to eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time. Do not drink or consume any of the products at any time. Follow the instructions on the bottles. The products mentioned are meant to be used on surfaces and hands to sanitize to protect against bacteria and viruses. CleanGo GreenGo is not a cure, nor does it imply to be a cure for COVID-19.

For further information please contact:
Rahim Mohamed
Chief Executive Officer
Phone: (403) 605-9429
RM@softlab9.com
https://www.soft-lab9.com/

Paul Searle
Corporate Communications
Citygate Capital Corp
Phone: (778) 240-7724
psearle@citygatecap.com

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Forward-Looking Information
This news release contains forward-looking statements and forward-looking information (collectively, "forward-looking statements") within the meaning of applicable Canadian and U.S. securities legislation, including the United States Private Securities Litigation Reform Act of 1995. All statements in this presentation that are not purely historical are forward-looking statements and include statements regarding beliefs, plans, expectations, and orientations regarding the future, including without limitation statements related to the use of the proceeds of the Private Placement and the Company's prospect of success in executing its proposed plans, including its plans to complete the acquisition of CleanGo GreenGo. Forward-looking statements can often be identified by words such as "will", "plans", "expects", "may", "intends", "anticipates", "believes", proposes" or variations of such words including negative variations thereof and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved. Forward-looking statements are based on certain assumptions by management regarding the Company, including, without limitation, the Company's ability to acquire CleanGo GreenGo and obtain required regulatory approvals and the timing thereof. Actual results could differ from those projected in any forward-looking statements due to numerous factors including, risks and uncertainties relating to the inability of the Company, to, among other things, obtain any required governmental, regulatory or stock exchange approvals, permits, consents or authorizations required to execute its proposed business plans, and obtain the financing required to carry out its planned future activities. Other factors such as general economic, market or business conditions or changes in laws, regulations and policies affecting the Company's operations may also adversely affect the future results or performance of the Company. The Company can provide no guarantee that it will be successful in completing the Private Placement or completing the acquisition of CleanGo GreenGo. Investors are cautioned that forward looking statements are not guarantees of future performance or events and, accordingly are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements. The forward-looking statements included in this news release are made as of the date hereof and the Company does not intend to update or revise any forward-looking statements, except as expressly required by law.

SOURCE: Softlab9 Technologies Inc

ReleaseID: 602298

PLANEGG/MUNICH, GERMANY and WILMINGTON, DE / ACCESSWIRE / August 18, 2020 / MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) and Incyte (Nasdaq:INCY) today announced that Monjuvi® (tafasitamab-cxix), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, has been included in the latest National Comprehensive Cancer Network® Clinical Practice Guidelines (NCCN Guidelines®) in Oncology for B-cell Lymphomas. Specifically, the NCCN Guidelines in the United States now include Monjuvi in combination with lenalidomide with a Category 2A designation as an option for the treatment of previously-treated adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma who are ineligible for autologous stem cell transplant (ASCT).

"We are very gratified the NCCN acted quickly to include Monjuvi in combination with lenalidomide with a Category 2A designation in its Clinical Practice Guidelines in Oncology as a treatment for patients with relapsed or refractory DLBCL who are not candidates for transplant. This targeted therapeutic option helps address an immediate medical need for patients who previously had limited treatment options," said Dr. Malte Peters, Chief Research & Development Officer, MorphoSys. "There is no other FDA-approved second line treatment for these patients with a 2A designation within the NCCN guidelines."

The U.S. Food and Drug Administration (FDA) approved Monjuvi in combination with lenalidomide under accelerated approval on July 31, 2020, for the treatment of adult patients with relapsed or refractory DLBCL not otherwise specified, including DBLCL arising from low grade lymphoma, and who are not eligible for ASCT. The approval was based on data from the MorphoSys-sponsored Phase 2 L-MIND study, an open label, multicenter single arm trial. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).1

The NCCN is a not-for-profit alliance of 30 leading cancer centers devoted to patient care, research and education. The intent of the NCCN Guidelines is to assist in the decision-making process of individuals involved in cancer care – including physicians, nurses, pharmacists, payers, patients and their families – with the ultimate goal of improving patient care and outcomes.

"The inclusion of Monjuvi in the NCCN Guidelines will help further inform healthcare providers of this advancement for patients," said Peg Squier, M.D., Group Vice President, U.S. Medical Affairs, Incyte. "We believe Monjuvi has the potential to address an urgent medical need for patients with relapsed or refractory DLBCL and are pleased that the NCCN has acknowledged the clinical benefit of this targeted therapeutic option."

DLBCL is the most common type of non-Hodgkin lymphoma in adults worldwide,2 characterized by rapidly growing masses of malignant B-cells in the lymph nodes, spleen, liver, bone marrow or other organs. It is an aggressive disease with about one in three patients not responding to initial therapy or relapsing thereafter.3 In the United States each year, approximately 10,000 patients are diagnosed with relapsed or refractory DLBCL who are not eligible for ASCT.4,5,6

The updated NCCN Guidelines are available at www.nccn.org.

NCCN® and the NCCN Guidelines® are registered trademarks of National Comprehensive Cancer Network.

About Monjuvi® (tafasitamab-cxix)

Monjuvi is a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody. In 2010, MorphoSys licensed exclusive worldwide rights to develop and commercialize tafasitamab from Xencor, Inc. Tafasitamab incorporates an XmAb® engineered Fc domain, which mediates B-cell lysis through apoptosis and immune effector mechanism including antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP).

Monjuvi is approved by the U.S. Food and Drug Administration in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT).

In January 2020, MorphoSys and Incyte entered into a collaboration and licensing agreement to further develop and commercialize Monjuvi globally. Monjuvi will be co-commercialized by Incyte and MorphoSys in the United States. Incyte has exclusive commercialization rights outside the United States.

A marketing authorization application (MAA) seeking the approval of tafasitamab in combination with lenalidomide in the EU has been validated by the European Medicines Agency (EMA) and is currently under review for the treatment of adult patients with relapsed or refractory DLBCL, including DLBCL arising from low grade lymphoma, who are not candidates for ASCT.

Tafasitamab-cxix is being clinically investigated as a therapeutic option in B-cell malignancies in a number of ongoing combination trials.

Monjuvi® is a registered trademark of MorphoSys AG.

XmAb® is a registered trademark of Xencor, Inc.

Important Safety Information
What are the possible side effects of MONJUVI?
MONJUVI may cause serious side effects, including:

Infusion reactions. Your healthcare provider will monitor you for infusion reactions during your infusion of MONJUVI. Tell your healthcare provider right away if you get chills, flushing, headache, or shortness of breath during an infusion of MONJUVI.
Low blood cell counts (platelets, red blood cells, and white blood cells). Low blood cell counts are common with MONJUVI, but can also be serious or severe. Your healthcare provider will monitor your blood counts during treatment with MONJUVI. Tell your healthcare provider right away if you get a fever of 100.4°F (38°C) or above, or any bruising or bleeding.
Infections. Serious infections, including infections that can cause death, have happened in people during treatments with MONJUVI and after the last dose. Tell your healthcare provider right away if you get a fever of 100.4°F (38°C) or above, or develop any signs and symptoms of an infection.

The most common side effects of MONJUVI include:

Feeling tired or weak
Diarrhea
Cough
Fever
Swelling of lower legs or hands
Respiratory tract infection
Decreased appetite

These are not all the possible side effects of MONJUVI.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Before you receive MONJUVI, tell your healthcare provider about all your medical conditions, including if you:

Have an active infection or have had one recently.
Are pregnant or plan to become pregnant. MONJUVI may harm your unborn baby. You should not become pregnant during treatment with MONJUVI. Do not receive treatment with MONJUVI in combination with lenalidomide if you are pregnant because lenalidomide can cause birth defects and death of your unborn baby.

You should use an effective method of birth control (contraception) during treatment and for at least 3 months after your final dose of MONJUVI.
Tell your healthcare provider right away if you become pregnant or think that you may be pregnant during treatment with MONJUVI.

Are breastfeeding or plan to breastfeed. It is not known if MONJUVI passes into your breastmilk. Do not breastfeed during treatment for at least 3 months after your last dose of MONJUVI.

You should also read the lenalidomide Medication Guide for important information about pregnancy, contraception, and blood and sperm donation.

Tell your healthcare provider about all the medications you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Please see the full Prescribing Information for Monjuvi, including Patient Information, for additional Important Safety Information.

About MorphoSys
MorphoSys is a commercial-stage biopharmaceutical company dedicated to the discovery, development and commercialization of exceptional, innovative therapies for patients suffering from serious diseases. The focus is on cancer. Based on its leading expertise in antibody, protein and peptide technologies, MorphoSys, together with its partners, has developed and contributed to the development of more than 100 product candidates, 27 of which are currently in clinical development. In 2017, Tremfya®, marketed by Janssen for the treatment of plaque psoriasis, became the first drug based on MorphoSys' antibody technology to receive regulatory approval. Headquartered near Munich, Germany, the MorphoSys group, including the fully owned U.S. subsidiary MorphoSys US Inc., has ~500 employees. More information at www.morphosys.com.

Tremfya® is a registered trademark of Janssen Biotech.

About Incyte
Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.

MorphoSys Forward-Looking Statements
This communication contains certain forward-looking statements concerning the MorphoSys group of companies, including the expectations regarding Monjuvi's ability to treat patients with relapsed or refractory diffuse large B-cell lymphoma, the further clinical development of tafasitamab-cxix, including ongoing confirmatory trials, additional interactions with regulatory authorities and expectations regarding future regulatory filings and possible additional approvals for tafasitamab-cxix as well as the commercial performance of Monjuvi. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "would," "could," "potential," "possible," "hope" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve known and unknown risks and uncertainties, which might cause the actual results, financial condition and liquidity, performance or achievements of MorphoSys, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if MorphoSys' results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Among the factors that may result in differences are MorphoSys' expectations regarding risks and uncertainties related to the impact of the COVID-19 pandemic to MorphoSys' business, operations, strategy, goals and anticipated milestones, including its ongoing and planned research activities, ability to conduct ongoing and planned clinical trials, clinical supply of current or future drug candidates, commercial supply of current or future approved products, and launching, marketing and selling current or future approved products, the global collaboration and license agreement for tafasitamab, the further clinical development of tafasitamab, including ongoing confirmatory trials, and MorphoSys' ability to obtain and maintain requisite regulatory approvals and to enroll patients in its planned clinical trials, additional interactions with regulatory authorities and expectations regarding future regulatory filings and possible additional approvals for tafasitamab-cxix as well as the commercial performance of Monjuvi, MorphoSys' reliance on collaborations with third parties, estimating the commercial potential of its development programs and other risks indicated in the risk factors included in MorphoSys' Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. MorphoSys expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation.

Incyte Forward-Looking Statements
Except for the historical information set forth herein, the matters set forth in this press release contain predictions, estimates and other forward-looking statements, including without limitation statements regarding: Monjuvi's potential to address an urgent medical need for patients with relapsed or refractory diffuse large B-cell lymphoma. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: the efficacy and safety of Monjuvi; the acceptance of Monjuvi in the marketplace; determinations made by the FDA and regulatory agencies outside of the United States; the effects of market competition; and other risks detailed from time to time in Incyte's reports filed with the U.S. Securities and Exchange Commission, including its quarterly report on Form 10-Q for the quarter ending June 30, 2020. Incyte disclaims any intent or obligation to update these forward-looking statements.

References:

Monjuvi® (tafasitamab-cxix) Prescribing Information. Boston, MA, MorphoSys.
Sarkozy C, et al. Management of relapsed/refractory DLBCL. Best Practice Research & Clinical Haematology. 2018 31:209-16. doi.org/10.1016/j.beha.2018.07.014.
Skrabek P, et al. Emerging therapies for the treatment of relapsed or refractory diffuse large B cell lymphoma. Current Oncology. 2019 26(4): 253-265. doi.org/10.3747/co.26.5421.
DRG Epidemiology data.
Kantar Market Research (TPP testing 2018).
Friedberg, Jonathan W. Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Hematology Am Soc Hematol Educ Program 2011; 2011:498-505. doi: 10.1182/asheducation-2011.1.498.

For more information, please contact:

MorphoSys

Media Contacts:
Jeanette Bressi
Director, US Communications
Tel: +1 617-404-7816
media@morphosys.com

Investor Contacts:
Dr. Anja Pomrehn
Senior Vice President
Tel: +49 (0)89 / 899 27 26972
anja.pomrehn@morphosys.com

Dr. Anca Ammon
Associate Director
Tel: +49 (0)89 899 27 26738
media@morphosys.com

Dr. Julia Neugebauer
Director
Tel: +49 (0)89 / 899 27 179
julia.neugebauer@morphosys.com

Incyte

Media Contacts:
Catalina Loveman
Executive Director, Public Affairs
Tel: +1 302 498 6171
cloveman@incyte.com

Investor Contact:
Dr. Michael Booth
Division VP, IR & Global Responsibility
Tel: +1 302 498 5914
mbooth@incyte.com

Jenifer Antonacci
Senior Director, U.S. Public Affairs
Tel: +1 302 498 7036
jantonacci@incyte.com

SOURCE: MorphoSys AG via EQS Newswire

ReleaseID: 602236

TAMPA, FL / ACCESSWIRE / August 18, 2020 / Travel restrictions due to the COVID-19 pandemic have canceled getaways and forced travelers to keep adding to their bucket lists. Avid traveler Justin Belill believes Peru should be a country at the top of your travel list when flights and safe travel around the globe resume.

Justin Belill is a member of the U.S. military and a former employee for two airlines, AirTran and Delta Air Lines. He has always had a major interest in airlines, aviation, travel, and experience cultures around the globe. As an avid explorer, Justin Belill has visited several countries that have proven absolutely unforgettable — one of them is Peru.

"To me, Peru is one of the most interesting countries in the world," Justin Belill said. "It's overflowing with culture, natural beauty, unique cuisine, and all of the makings of an ideal bucket-list destination."

Justin Belill explained that one of his top reasons to visit Peru is to meet the people who call it home. Heritage isn't something that has been put on the back burner in Peru. In fact, many Peruvians still have direct links to Inca ancestors, which mean visitors can still experience Inca traditions, ancient recipes, and more. Justin Belill explained that Peruvian people tend to be incredibly helpful, peaceful, and polite, making asking questions and sharing stories that much more enjoyable.

"When many travelers think of Peru, they think Machu Picchu," Justin Belill said. "But Peru is amazingly home to more than 28 unique climates."

Justin Belill stated that Machu Picchu is surely iconic and bucket-list-worthy in itself. However, Peru offers far more than just one iconic destination. The Ballestas Islands are loaded with penguins, Paracas is a charming desert town, and the Canon del Cotahuasi is one of the deepest canyons in the world. From the peaks of the Andes to the deep blue hues of the Pacific Ocean, Peru is packed with must-visit scenery, towns, and other destinations.

"Food critics consistently name Peru as one of the top foodie destinations in the Americas," Justin Belill said. "You'll understand why within hours of arrival."

Peruvian dishes are known for being spicy and filling, including the unique guinea pig meat, known as cuy, found in the Andes. Other, more traditional, Peruvian foods include mouthwatering empanadas, fresh ceviche near the sea, lomo saltado, butifarra, and more. Justin Belill explained that because the country is home to so many unique climates, the foods vary drastically based on the areas you visit.

"It's impossible to pack all of the beauty, culture, and flavors of Peru into a single visit, but I encourage you to try," Justin Belill finished. "You won't be disappointed."

CONTACT:

Caroline Hunter
Web Presence, LLC
+1 7865519491

SOURCE: Justin Belill

ReleaseID: 602270

HOUSTON, TX / ACCESSWIRE / August 18, 2020 / Evolution Petroleum Corporation (NYSE American:EPM) ("Evolution" or the "Company") today disclosed its independently determined reserve estimates as of June 30, 2020, declared its next quarterly cash dividend, and announced that it will release its financial and operational results for fiscal year 2020 on September 9, 2020.

Cash Dividend

Evolution's board of directors has declared a cash dividend of $0.025 per share of common stock to be paid on September 30, 2020 to shareholders of record as of September 15, 2020. This will be the 28th consecutive quarterly dividend paid to shareholders, and the Company has paid out to shareholders more than $70 million in cash dividends since initiating dividends in 2013. The Company's goal is to return the majority of operating cash flow to shareholders through dividends while retaining sufficient cash for re-investment to support its strategy.

Reserves as of June 30, 2020

Proved Reserves

Oil

(Mbbl)

Natural Gas Liquids

(Mbbl)

Oil Equivalent

(Mbbl)

Proved Developed Producing

 
 
6,578
 
 
 
1,777
 
 
 
8,355
 
 
 
82%
 

Proved Undeveloped

 
 
1,648
 
 
 
216
 
 
 
1,864
 
 
 
18%
 

Total Proved

 
 
8,226
 
 
 
1,993
 
 
 
10,219
 
 
 
100%
 

 
 
81%
 
 
 
19%
 
 
 
100%
 
 
 
 
 

Probable Reserves

Oil

(Mbbl)

Natural Gas Liquids

(Mbbl)

Oil Equivalent

(Mbbl)

Probable Developed Producing Producing

 
 
2,199
 
 
 
662
 
 
 
2,861
 
 
 
86%
 

Probable Undeveloped

 
 
450
 
 
 
0
 
 
 
450
 
 
 
14%
 

Total Probable

 
 
2,649
 
 
 
662
 
 
 
3,311
 
 
 
100%
 

 
 
80%
 
 
 
20%
 
 
 
100%
 
 
 
 
 

Possible Reserves

Oil

(Mbbl)

Natural Gas Liquids

(Mbbl)

Oil Equivalent

(Mbbl)

Possible Developed Producing

 
 
2,246
 
 
 
492
 
 
 
2,738
 
 
 
89%
 

Possible Undeveloped

 
 
326
 
 
 
0
 
 
 
326
 
 
 
11%
 

Total Possible

 
 
2,572
 
 
 
492
 
 
 
3,064
 
 
 
100%
 

 
 
84%
 
 
 
16%
 
 
 
100%
 
 
 
 
 

Evolution's reserves, 100% of which are oil and natural gas liquids, are determined by DeGolyer and MacNaughton, a global independent reservoir engineering firm. The oil price used were based on West Texas Intermediate pricing, calculated as the unweighted arithmetic average of the first day of the month price for each month within the 12-month period prior to the end of the reporting period was $47.37 per barrel. The probable and possible reserves are categories that represent potential recoveries from the CO2 flood developed in the Delhi Field greater than that included in the proved reserves. Consequently, while the probable and possible reserves are 86% and 89% developed, respectively, and require de minimis conformance capital expenditures, they remain less certain of attainment and have more risk of recovery than proved reserves and should not be aggregated with other categories.

"Despite what has been a difficult and unprecedented period both for our industry as well as our economy due to Covid-19, we are fortunate to have strategically built our company around long-life, low decline quality oil assets with attractive non-proven potential upside. The acquisition we completed during the year helped to offset produced volumes and the effect of lower commodity prices." said Jason Brown, President and CEO.

"That being said, the financial limitations of the operator at Delhi significantly reduced their investment in the field during fiscal 2020, which directly impacted production. Historically we have been able to hold production relatively flat through conformance and infill drilling projects. In addition, the purchased CO2 line to Delhi has been offline since late February for an unscheduled issue that is currently being repaired by the pipeline operator, which significantly reduced the rate of injections in the field. We have been informed that it will be back online during the fourth quarter of calendar 2020 and should provide additional pressure support to the field. Denbury's projected near-term emergence from bankruptcy proceedings is expected to restart conformance work and accelerate Test Site 5 expansion to May of 2021. We continue to have a great working relationship with our operators at both Delhi and Hamilton Dome, allowing us to focus our efforts on acquiring additional long-life, quality assets that can support and sustain our dividend. I also wish to emphasize that Denbury's bankruptcy does not affect our ownership interests in the Delhi Field."

Investor Conference Call

Evolution will release its financial and operational results for the fiscal year ended June 30, 2020 after the stock market closes on Wednesday, September 9, 2020. An investor conference call to review the results will be held on Thursday, September 10, 2020 at 10:00 a.m. Eastern (9:00 a.m. Central). Details for the conference call are as follows:

Date: Thursday, September 10, 2020
Time: 10:00 a.m. Eastern (9:00 a.m. Central)
Call: 1-844-369-8770 (United States & Canada)
Call: 1-862-298-0840 (International)

To listen live via webcast over the internet, go to http://www.webcaster4.com/Webcast/Page/2188/36736. A replay will be available two hours after the end of the conference call through October 10, 2020 and will be accessible by calling 1-877-481-4010 (United States & Canada); 1-919-882-2331 (International) with the replay passcode number of 36736.

Investor Conference Presentation

Evolution today announced that the Company will participate in the virtual Midwest IDEAS Investor Conference on August 26, 2020. The Company's presentation will be webcasted and is scheduled to be available at 7:00 am CST on August 26, 2020, and the Company will host 1×1 investor meetings. The presentation can be accessed through the Midwest IDEAS conference portal for registered participants, or in the investor relations section of the Company's website: http://www.EvolutionPetroleum.com.

About Evolution Petroleum

Evolution Petroleum Corporation is an oil company focused on delivering a sustainable dividend yield to its shareholders through the ownership, management, and development of producing oil and gas properties. The Company's long-term goal is to build a diversified portfolio of oil and gas assets primarily through acquisition, while seeking opportunities to maintain and increase production through selective development, production enhancement and other exploitation efforts on its properties. Evolution's largest asset is our interests in a CO2 enhanced oil recovery project in Louisiana's Delhi field. We also own interests in a secondary recovery project in Wyoming's Hamilton Dome field. Additional information, including the Company's annual report on Form 10-K and its quarterly reports on Form 10-Q, is available on its website at www.EvolutionPetroleum.com.

Cautionary Statement

All forward-looking statements contained in this press release regarding potential results and future plans and objectives of the Company involve a wide range of risks and uncertainties. Statements herein using words such as "believe," "expect," "plans," "outlook" and words of similar meaning are forward-looking statements. Although our expectations are based on business, engineering, geological, financial and operating assumptions that we believe to be reasonable, many factors could cause actual results to differ materially from our expectations and we can give no assurance that our goals will be achieved. These factors and others are detailed under the heading "Risk Factors" and elsewhere in our periodic reports filed with the SEC. The Company undertakes no obligation to update any forward-looking statement.

Company Contacts:

Jason Brown, President & CEO
David Joe, SVP & CFO
(713) 935-0122

SOURCE: Evolution Petroleum Corporation

ReleaseID: 602233

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES

TORONTO, ON / ACCESSWIRE / August 18, 2020 / Amex Exploration Inc. ("Amex" or the "Company") (TSXV:AMX) is pleased to announce that it has entered into an agreement with a syndicate of underwriters led by PI Financial Corp. (collectively, the "Underwriters"), pursuant to which the Underwriters have agreed to purchase, on a "bought deal" private placement basis, 1,600,000 flow-through common share (the "Flow-Through Shares") of the Company, at a price per Flow-Through Share of $5.85 (the "Issue Price"), for gross proceeds of C$9,360,000 (the "Offering"). The Issue Price represents a premium of approximately 69% to the closing price of the Corporation's common shares on the TSX Venture Exchange on August 17, 2020.

The Flow-Through Shares will qualify as "flow-through shares" (within the meaning of subsection 66(15) of the Income Tax Act (Canada) and section 359.1 of the Taxation Act (Québec)).

The Company has also granted the underwriters an option to purchase up to an additional 400,000 Flow-Through Shares to cover over-allotments, exercisable in whole or in part at any time prior to the closing date of the Offering.

The gross proceeds from the sale of the Flow-Through Shares will be used for general exploration expenditures on Amex's properties located in Quebec.

Victor Cantore, President and CEO of Amex Exploration commented, "We are pleased to see the continued support from our largest shareholder and to welcoming a new cornerstone investor in connection with this transaction."

The Offering is scheduled to close on or about September 9, 2020, or such other date as agreed between the Company and the underwriters, and is subject to certain conditions including, but not limited to, the receipt of all necessary regulatory and other approvals including the approval of the TSX Venture Exchange.

In connection with the Offering, the underwriters will receive on closing of the Offering: (i) a cash commission of 6.0% of the gross proceeds of the Offering, excluding gross proceeds from the issuance of Flow-Through Shares on a president's list to be agreed upon by the Company and the Underwriters (the "President's List") for which a commission of 3.0% of such gross proceeds will be paid by the Company to the Underwriters. The Underwriters are working with a charitable promoter in respect of the sale of the Flow-Through Shares.

This news release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

About Amex

Amex Exploration Inc. is a junior mining exploration company, the primary objective of which is to acquire, explore, and develop viable gold and base metal projects in the mining-friendly jurisdictions of Quebec. Amex is focused on its 100% owned Perron gold project located 110 kilometers north of Rouyn Noranda, Quebec, consisting of 116 contiguous claims covering 4,518 hectares. A number of significant gold discoveries have been made at Perron, including the Eastern Gold Zone, the Gratien Gold Zone, the Grey Cat Zone, and the Central Polymetallic Zone. High-grade gold has been identified in each of the zones. A significant portion of the project remains underexplored. In addition to the Perron project, the Company holds a portfolio of three other properties focused on gold and base metals in the Abitibi region of Quebec and else where in the province.

For further information please contact:

Victor Cantore
President and Chief Executive Officer
Amex Exploration: 514-866-8209

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements:

This news release contains forward-looking statements. All statements, other than of historical facts, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future including, without limitation, the completion of the Offering as described herein are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "to earn", "to have', "plan" or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, failure to obtain any necessary regulatory approvals, the termination of any agreement governing the Offering, general business and economic conditions, changes in world gold markets, sufficient labour and equipment being available, changes in laws and permitting requirements, unanticipated weather changes, title disputes and claims, environmental risks as well as those risks identified in the Company's annual Management's Discussion and Analysis. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results may vary materially from those described and accordingly, readers should not place undue reliance on forward-looking statements. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update these forward-looking statements except as otherwise required by applicable law.

SOURCE: Amex Exploration Inc.

ReleaseID: 602278

VANCOUVER, BC / ACCESSWIRE / August 18, 2020 / United Battery Metals Corp. (CSE:UBM) (OTC:UBMCF) (FWB:0UL) ("UBM" or the "Company") is pleased to announce that it has completed a private placement (the "Private Placement") of 19,998,858 units (each, a "Unit"), at a price of $0.11 per Unit, for total gross proceeds of 2,199,874.38. Each Unit consists of one common share and one common share purchase warrant, with each warrant being exercisable to acquire an additional common share at a price of $0.25 for a period of twenty-four months.

The Company intends to use the proceeds of the Private Placement for working capital and general corporate purposes, including with respect to its search for suitable lithium and other battery materials- related mineral properties to add to its portfolio.

All securities issued in connection with the Private Placement will be subject to a four-month- and-one-day statutory hold period in accordance with applicable securities laws. Completion of the placement remains subject to the approval of the Canadian Securities Exchange (the "CSE").

ON BEHALF OF THE BOARD OF DIRECTORS

"Michael Dehn"

CEO

For further information, please contact the Company at: (604) 428-9063.

The CSE does not accept responsibility for the adequacy or accuracy of this release.

This news release includes forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking, including all statements in regard to the Company's intention to complete the Private Placement and with respect to the Company's search for suitable additional mineral properties. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements; in this regard, there is a risk that the Private Placement may not be completed as contemplated, or at all, and that the Company may not be able to identify or acquire any additional mineral properties. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, obtaining necessary approval from the CSE, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.

SOURCE: United Battery Metals Corp.

ReleaseID: 602231